Tranexamic acid is a synthetic derivative of lysine used as an antifibrinolytic in the treatment and prevention of major bleeding. It possesses a similar mechanism of action to aminocaproic acid but is approximately 10-fold more potent.
It was first patented in 1957 and received its initial US approval in 1986.
Taken orally, tranexamic acid is indicated for the treatment of hereditary angioedema, cyclic heavy menstrual bleeding in premenopausal females, and other instances of significant bleeding in the context of hyperfibrinolysis. Given intravenously, tranexamic acid is indicated for short-term use (2-8 days) in patients with hemophilia to prevent or reduce bleed...
Acibadem Maslak Hospital, Istanbul, Sariyer, Turkey
Maasstad Hospital, Rotterdam, Zuid-Holland, Netherlands
Red Cross Hospital, Beverwijk, Noord-Holland, Netherlands
Martini Hospital, Groningen, Netherlands
Asociación Instituto Biodonostia, San Sebastián, Guipuzcoa, Spain
Assuta ashdod, Ashdod, Shfela, Israel
Cairo University, Cairo, Egypt
Elda University Hospital, Elda, Alicante, Spain
Nefise Nazlı YENIGUL, Bursa, Turkey
George Washington University Hospital, Washington, District of Columbia, United States
Inova Health System, Falls Church, Virginia, United States
Haseki TRH, Istanbul, Sultangazi, Turkey
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.